Skip to main content
. Author manuscript; available in PMC: 2018 Oct 3.
Published in final edited form as: Cell Metab. 2017 Sep 14;26(4):672–685.e4. doi: 10.1016/j.cmet.2017.08.019

Figure 6. Gut microbiota mediates the effects of EODF on metabolic syndrome in DIO mice.

Figure 6

(A) Body weight. Before EODF or microbiota transplantation (MT) treatment, all mice were given access to control vehicle (CV) water or water supplemented with an antibiotics cocktail (AB) for 4 weeks. n=6–8 mice/group.

(B) Fat mass. n=6–8 mice/group.

(C) Serum ALT. n=6–8 mice/group.

(D) Liver triglycerides. n=6–8 mice/group.

(E) Representative H & E staining of liver sections. Scale bar: 100 μm.

(F–G) Glucose tolerance test in CV-treated (F) or AB-treated (G) mice. n=6 mice/group.

(H) Glucose tolerance test in MT mice receiving microbiota from AL (AL/MT) or EODF donors (EODF/MT). n= 8 mice/group.

Data are presented as mean ± SEM. Different lowercase letters indicate statistical significance by two-tailed unpaired t-test, a, p < 0.05; b, p < 0.01; c, p < 0.005; and d, p < 0.001. Black letters show the effects of EODF or EODF/TM (EODF versus AL, or EODF/MT versus AL/MT with access to the same water).